Benign Intraductal Papilloma without Atypia on Core Needle Biopsy Has a Low Rate of Upgrading to Malignancy after Excision

Song-Hee Han1,2, Milim Kim1, Yul Ri Chung2, Bo La Yun3, Mijung Jang1, Sun Mi Kim1, Eunyoung Kang4, Eun-Kyu Kim4, So Yeon Park1

1Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; 2Department of Pathology, Konyang University Hospital, Daejeon; Departments of 3Radiology and 4Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

INTRODUCTION

Intraductal papilloma (IDP) originates from both the large ducts of the subareolar region and the terminal duct lobular unit in the periphery, and it is histologically characterized by a fibrovascular core covered with epithelial and myoepithelial cells. It is a relatively common lesion found in breast biopsies. However, IDP often accompanies a variety of changes, including sclerosis, epithelial or myoepithelial hyperplasia, squamous or apocrine metaplasia, and even atypical proliferation [1].

A papilloma with atypia, which encompasses atypical ductal hyperplasia (ADH) or small foci of low-grade ductal carcinoma in situ (DCIS) within the papilloma, has an increased risk of developing malignancy and has been reported to show a high rate of upgrading on subsequent excision [2-5]. Thus, surgical excision is usually recommended for IDP with atypia diagnosed by core needle biopsy (CNB) as standard management. On the contrary, no consensus has been met regarding the management of benign IDP without atypia, suggesting careful observation rather than surgical excision [7-11]. However, most of the previous studies were performed using small samples, and some studies included IDP with atypia or even malignancy in their settings.

The management of benign intraductal papilloma (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial. This study was performed to evaluate the rate of upgrading to malignancy or high-risk lesions after excision and to identify factors associated with upgrading using a large series of benign IDP cases without atypia. Methods: We included patients who were diagnosed as having benign IDP without atypia on CNB and underwent surgical or vacuum-assisted excision between 2010 and 2015. We analyzed the clinical, radiologic, and histopathologic features of IDPs that were upgraded to malignancy or high-risk lesions after excision. Results: A total of 511 benign IDPs without atypia diagnosed via CNB were identified, of which 398 cases were treated with excision. After reviewing these cases, four cases of high-risk lesions in adjacent tissue on CNB, two cases which were revealed as papilloma with atypia, and nine cases of malignancy in the same breast were excluded. In the remaining 383 cases, the rate of upgrading to malignancy and high-risk lesions after excision was 0.8% and 4.4%, respectively. The presence of concurrent contralateral breast cancer, the presence of symptoms, and multifocality were factors significantly associated with upgrading to malignancy on subsequent excision. Surgical excision rather than vacuum-assisted excision was significantly associated with upgrading to high-risk lesions or malignancy. Conclusion: The rate of upgrading to malignancy for benign IDP without atypia was very low, suggesting that close clinical and radiologic observation may be sufficient for patients with benign IDP without atypia on CNB under proper settings.

Key Words: Breast neoplasms, Large-core needle biopsy, Observation, Papilloma
In the present study, we restricted our analysis to a large cohort of benign IDPs without atypia, and we evaluated the upgrade rate to malignancy, including DCIS and invasive carcinoma. In addition, evaluation of the presence of proliferative lesions with atypia, such as ADH, atypical lobular hyperplasia, and lobular carcinoma in situ, which are associated with a high risk for developing breast cancer, is also important in assessing breast cancer risk and determining patient management. Thus, we evaluated the upgrade rate to these high-risk lesions as well. Furthermore, we analyzed the clinicopathologic features associated with upgrading on excision.

**METHODS**

**Case selection**

We performed a retrospective search of the pathology database to identify IDPs without atypia diagnosed via CNB between January 2010 and December 2015 at the Department of Pathology, Seoul National University Bundang Hospital, Korea. All CNBs were performed using a 14-gauge automated biopsy gun (Stericut®; TSK Laboratory, Tochigi, Japan) under ultrasound guidance by radiologists specialized in breast imaging. We selected cases that were excised with lumpectomy, excisional biopsy, or vacuum-assisted excision (VAE) at our institution. When patients presented with symptoms such as bloody nipple discharge or a palpable mass or when IDP was located near the skin or nipple, surgical management was recommended. When the lesion was single with a size less than 3 cm and located far from the skin or nipple, patients had an option of surgery or VAE. VAE was performed using an 8- or 11-gauge vacuum-assisted biopsy needle (Mammotome®; Devicor Medical Products, Cincinnati, USA).

Benign IDPs with benign proliferative lesions, such as usual ductal hyperplasia or adenosis, and those associated with sclerosis, radial scars, fibrocystic changes, and columnar cell changes, were included. IDPs coexisting with a malignant lesion, including invasive carcinoma and DCIS, or other high-risk lesions, such as ADH and lobular neoplasia (atypical lobular hyperplasia and lobular carcinoma in situ), in the same side of the breast were excluded. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (protocol number: B-1708-414-107) and informed consent was waived.

**Evaluation of clinical and radiologic features**

Clinical variables, such as the age at the time of diagnosis; gender; cause of detection; clinical symptoms, including nipple discharge, palpable mass, and local pain; and history of breast cancer, were recorded. Radiologic findings, including the location of the lesion, size of the lesion defined as the largest dimension recorded on imaging, Breast Imaging Reporting and Data System (BI-RADS) classification of the lesion, multifocality, and the number of tissue cores in CNB, were retrieved from the medical records. Multifocality was defined as two or more lesions separated by normal breast tissue in imaging that were eventually proven to be benign IDPs on pathologic examination.

To analyze the radiologic-pathologic concordance, we reviewed all radiologic findings in each case and matched them with the pathologic diagnosis by the location of the CNB and the size of the lesion. Radiologic-pathologic discordance was considered to be present when the lesion was more than moderately suspicious for malignancy in radiologic findings, i.e., BI-RADS category 4b, 4c, or 5, but for which the histologic findings of IDP without atypia did not account for the imaging pattern.

**Statistical analysis**

Statistical analysis was performed using SPSS version 21.0 software (IBM Corp., Armonk, USA). For patients with more than one IDP, analyses of the radiologic and pathologic features were based on each IDP. Chi-square tests or Fisher exact tests were used to compare the clinicopathologic variables between upgraded lesions and nonupgraded lesions. Statistical significance was defined as a p-value < 0.05. All reported p-values were two-sided.

**RESULTS**

**Clinical, radiologic, and pathologic characteristics of IDP on CNB**

A total of 511 benign IDPs without atypia diagnosed by CNB were identified, of which 398 cases were treated with surgical excision or VAE at our institution. After reviewing
the medical records, pathologic reports, and hematoxylin and eosin stained slides of the CNBs, four cases that had high-risk lesions in the adjacent tissue, two cases that were re-diagnosed as papilloma with atypia, and nine cases of concurrent breast cancer in the same breast were excluded. Finally, 383 cases of benign IDP without atypia were included in the analyses.

The median age of the patients at the time of biopsy was 48 years (range, 23–82 years). In this cohort, the two major causes of initial detection were routine mammographic screening on medical checkup (n = 224, 58.5%) and the presence of a symptom (n = 108, 28.2%). All breast CNBs were performed under ultrasound guidance. The median number of core biopsy samples was 5 (range, 1–15). The other baseline characteristics of the patients are described in Table 1.

**Table 1.** Baseline characteristics (n= 383)

| Characteristic                                             | No. (% )                 |
|------------------------------------------------------------|--------------------------|
| Age (yr)*                                                   | 48 (23–82)               |
| Cause of detection                                         |                          |
| Medical checkup                                            | 224 (58.5)               |
| Presence of symptom                                       | 108 (28.2)               |
| Nipple discharge                                           | 67                       |
| Palpable mass                                              | 34                       |
| Local pain                                                 | 7                        |
| Radiologic abnormality detected during examination of other lesions | 51 (13.3)               |
| Concurrent contralateral breast cancer                     |                          |
| Yes                                                       | 32 (8.4)                 |
| No                                                        | 351 (91.6)               |
| Side                                                       |                          |
| Right                                                     | 178 (46.5)               |
| Left                                                      | 205 (53.5)               |
| Subareolar location                                        |                          |
| Yes                                                       | 50 (13.1)                |
| No                                                        | 333 (86.9)               |
| Radiologic size (cm)*                                      | 0.8 (0.3–4.2)            |
| BI-RADS classification                                     |                          |
| C3                                                        | 2 (0.5)                  |
| C4a                                                       | 348 (90.9)               |
| C4b                                                       | 29 (7.6)                 |
| C4c                                                       | 4 (1.0)                  |
| Radiologic identification of intraductal lesion            |                          |
| Yes                                                       | 72 (18.8)                |
| No                                                        | 311 (81.2)               |
| Multifocality                                              |                          |
| No                                                        | 292 (76.2)               |
| Yes                                                       | 91 (23.8)                |
| No. of cores in CNB*                                       | 5 (1–15)                 |
| Method of procedure after CNB                              |                          |
| VAE                                                       | 226 (59.0)               |
| Surgical excision                                          | 157 (41.0)               |

BI-RADS = Breast Imaging Reporting and Data System; CNB = core needle biopsy; VAE = vacuum-assisted excision.

**Characteristics of IDPs with a likelihood of upgrading to malignancy or high-risk lesions on excision**

Among the 383 IDPs without atypia on CNB, 20 cases (5.2%) were upgraded to malignancy or high-risk lesions, including ADH and lobular neoplasia, on excision; 10 cases were upgraded to ADH, five to atypical lobular hyperplasia, two to lobular carcinoma in situ, and three to DCIS. The rate of upgrading to malignancy and high-risk lesions after excision was 0.8% (n = 3) and 4.4% (n = 17), respectively. We also

**Table 2.** Characteristics of intraductal papillomas without atypia upgraded to malignancy on subsequent excision

| Characteristic                                             | Not upgraded to malignancy (n=380) | Upgraded to malignancy (n=3) | p-value  |
|------------------------------------------------------------|------------------------------------|-------------------------------|----------|
| Age (yr)                                                   |                                    |                               | 0.260    |
| <50                                                       | 213 (56.1)                         | 3 (100)                       |          |
| ≥ 50                                                      | 167 (43.9)                         | 0                             |          |
| Side                                                       |                                    |                               | 0.099    |
| Right                                                     | 175 (46.1)                         | 3 (100)                       |          |
| Left                                                      | 205 (53.9)                         | 0                             |          |
| Subareolar area                                            |                                    |                               | 0.344    |
| Yes                                                       | 49 (12.9)                          | 1 (33.3)                      |          |
| No                                                        | 331 (87.1)                         | 2 (66.7)                      |          |
| Presence of symptom                                       |                                    |                               | 0.022    |
| Yes                                                       | 105 (27.6)                         | 3 (100)                       |          |
| No                                                        | 275 (72.4)                         | 0                             |          |
| Concurrent contralateral breast cancer                     |                                    |                               | 0.019    |
| Yes                                                       | 30 (7.9)                           | 2 (66.7)                      |          |
| No                                                        | 350 (92.1)                         | 1 (33.3)                      |          |
| Radiologic size (cm)*                                     |                                    |                               | 0.271    |
| <0.8                                                      | 158 (41.6)                         | 0                             |          |
| ≥ 0.8                                                     | 222 (58.4)                         | 3 (100)                       |          |
| BI-RADS classification                                    |                                    |                               | 0.409    |
| C3                                                        | 2 (0.5)                            | 0                             |          |
| C4a                                                       | 346 (91.1)                         | 2 (66.7)                      |          |
| C4b                                                       | 28 (7.4)                           | 1 (33.3)                      |          |
| C4c                                                       | 4 (1.0)                            | 0                             |          |
| Radiologic identification of intraductal lesion           |                                    |                               | 1.000    |
| Yes                                                       | 72 (18.9)                          | 0                             |          |
| No                                                        | 308 (81.1)                         | 3 (100)                       |          |
| Multifocality                                              |                                    |                               | 0.013    |
| No                                                        | 292 (76.8)                         | 0                             |          |
| Yes                                                       | 86 (23.2)                          | 3 (100)                       |          |
| No. of cores in CNB*                                      |                                    |                               | 0.569    |
| <5                                                        | 151 (40.5)                         | 2 (66.7)                      |          |
| ≥ 5                                                       | 222 (59.5)                         | 1 (33.3)                      |          |
| Method of procedure after CNB                             |                                    |                               | 0.068    |
| Surgical excision                                         | 154 (40.5)                         | 3 (100)                       |          |
| VAE                                                       | 226 (59.5)                         | 0                             |          |

p-values were calculated by Fisher exact test.

BI-RADS = Breast Imaging Reporting and Data System; CNB = core needle biopsy; VAE = vacuum-assisted excision.

*Information was available for 376 lesions.
evaluated the characteristics of the lesions upgraded to malignancy on excision. Interestingly, we found that the presence of a symptom \( (p = 0.022) \), the presence of concurrent contralateral breast cancer \( (p = 0.019) \), and multifocality of the lesions \( (p = 0.013) \) were predictive factors for upgrading to malignancy (Table 2). In addition, cases upgraded to malignancy or high-risk lesions were associated with surgical excision after CNB \( (p < 0.001) \). The presence of concurrent contralateral breast cancer tended to have an association with upgrading to malignancy or high-risk lesions \( (p = 0.075) \) (Table 3).

### Characteristics of the cases upgraded to malignancy on excision

The clinical and pathologic characteristics of the cases that were upgraded to malignant lesions are summarized in Table 4. All of these cases were upgraded to DCIS, which was found around the papilloma (Figure 1). The extent of the DCIS was 0.5 cm, 2.5 cm, and 2.5 cm in each case. Of these three cases, two were from the same patient. All of the cases had clinical symptoms: one manifested as nipple discharge and the others as a palpable mass. Radiologic size of the lesions was 0.8 cm or greater and showed multifocality. Two cases had concurrent contralateral breast cancer.

### DISCUSSION

Advances in screening and imaging techniques for breast cancer have resulted in an increased number of suspicious lesions, which in turn, have led to an increased number of breast biopsies. The incidence of papillary lesions, including IDPs, has increased steadily over the past decade [12]. However, management of benign IDPs without atypia diagnosed

### Table 3. Characteristics of intraductal papillomas without atypia upgraded to malignancy or other high-risk lesions on subsequent excision

| Characteristic                                             | Not upgraded to malignancy or high risk lesions \( (n=363) \) | Upgraded to malignancy or high risk lesions \( (n=20) \) | \( p \)-value |
|-----------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------|--------------|
| Age (yr)                                                   |                                                             |                                                        |              |
| \(< 50\)                                                   | 204 (56.2)                                                  | 12 (60.0)                                              | 0.739        |
| \(\geq 50\)                                                | 159 (43.8)                                                  | 8 (40.0)                                               |              |
| Location                                                  |                                                             |                                                        | 0.432        |
| Right                                                     | 167 (46.0)                                                  | 11 (55.0)                                              |              |
| Left                                                      | 196 (54.0)                                                  | 9 (45.0)                                               |              |
| Subareolar area                                            |                                                             |                                                        | 1.000        |
| Yes                                                       | 48 (13.2)                                                   | 2 (10.0)                                               |              |
| No                                                        | 315 (86.8)                                                  | 18 (90.0)                                              |              |
| Presence of symptom                                       |                                                             |                                                        | 0.854        |
| Yes                                                       | 102 (28.1)                                                  | 6 (30.0)                                               |              |
| No                                                        | 261 (71.9)                                                  | 14 (70.0)                                              |              |
| Concurrent contralateral breast cancer                     |                                                             |                                                        | 0.075        |
| Yes                                                       | 28 (7.7)                                                    | 4 (20.0)                                               |              |
| No                                                        | 335 (92.3)                                                  | 16 (80.0)                                              |              |
| Radiologic size (cm)                                      |                                                             |                                                        | 0.560        |
| \(< 0.8\)                                                 | 151 (43.6)                                                  | 7 (35.0)                                               |              |
| \(\geq 0.8\)                                              | 212 (58.4)                                                  | 13 (65.0)                                              |              |
| BI-RADS classification                                    |                                                             |                                                        | 0.319        |
| C3                                                        | 2 (0.6)                                                     | 0                                                      |              |
| C4a                                                       | 331 (91.2)                                                  | 17 (85.0)                                              |              |
| C4b                                                       | 27 (7.4)                                                    | 2 (10.0)                                               |              |
| C4c                                                       | 3 (0.8)                                                     | 1 (5.0)                                                |              |
| Radiologic identification of intraductal lesions           |                                                             |                                                        | 0.142        |
| Yes                                                       | 71 (19.6)                                                   | 1 (5.0)                                                |              |
| No                                                        | 292 (80.4)                                                  | 19 (95.0)                                              |              |
| Multifocality                                             |                                                             |                                                        | 0.278        |
| No                                                        | 279 (76.9)                                                  | 13 (65.0)                                              |              |
| Yes                                                       | 84 (23.1)                                                   | 7 (35.0)                                               |              |
| No. of cores in CNB*                                      |                                                             |                                                        | 0.687        |
| \(< 5\)                                                   | 144 (40.4)                                                  | 9 (45.0)                                               |              |
| \(\geq 5\)                                                | 212 (59.6)                                                  | 11 (55.0)                                              |              |
| Method of procedure after CNB                             |                                                             |                                                        | <0.001       |
| Surgical excision                                         | 139 (38.3)                                                  | 18 (90.0)                                              |              |
| VAE                                                       | 224 (61.7)                                                  | 2 (10.0)                                               |              |

\( \text{p-values were calculated by the chi-square or Fisher exact test.} \)

\( \text{BI-RADS=Breast Imaging Reporting and Data System; CNB=core needle biopsy; VAE=vacuum-assisted excision.} \)

\( \text{*Information was available for 376 lesions.} \)
by CNB remains controversial with some suggesting follow-up imaging and others excision. Moreover, in previous studies, the reported upgrading rates of benign IDP following excision vary widely [4,7-11,13-15]. This difference may have resulted from the study design, definition of upgrade lesions, and methodological details. Thus, we carefully selected our cohort to include only benign IDP cases diagnosed by CNB that had no malignant or high-risk lesions in the same breast. In this study, we showed that the rate of upgrading to malignancy was 0.8% at our institution. In addition, we found that the presence of a symptom, concurrent contralateral breast cancer, and multifocality were significant factors predictive of upgrading to malignancy. We also showed that upgrading to malignancy or high-risk lesions was associated with surgical excision rather than VAE. However, this may be caused by selection bias since patients with symptoms or multiple lesions were generally treated with surgical excision.

Several studies have attempted to identify factors that are associated with upgrading of benign IDP on subsequent excision [7,9,16-22]. It was reported that old age at diagnosis was associated with upgrading to malignancy in benign IDPs [16,22]. Regarding the size of the lesion, IDPs upgraded to malignancy have been reported to be larger [7,17,22]. Previously, we also showed that large-sized IDP was a significant predictor of an upgrade by analyzing solitary IDPs diagnosed at different time points at our institution, excluding patients with breast cancer [9]. Although the size of the IDP was not a significant factor associated with upgrading to malignancy in the present study, all upgraded cases were above the median in size. Besides the size of the lesion, Kil et al. [18] have suggested that peripherally located IDPs require additional surgical excision. Holley et al. [19] reported that a reduced amount of tissue collected at biopsy (three cores vs. five cores; 14-gauge vs. 9-gauge needle) was associated with an upgraded lesion. Additionally, previous studies have reported varying results regarding the impact of the BI-RADS category on upgrade rates in benign IDP [20,21].

Contrary to the previous studies, patient age, size, and location of the lesion, number of tissue cores, and BI-RADS score were not proven to be significant factors in our study. The most noticeable predictor of upgrading to malignancy was the presence of concurrent contralateral breast cancer, a finding that has never been reported in previous studies. While only 7.9% (30/380) of the nonupgraded cases had concurrent contralateral breast cancer, 66.7% (2/3) of upgraded cases had concurrent contralateral breast cancer. This association may be explained by the fact that the risk of developing new breast cancer is increased in patients with a history of breast cancer [23]. We also found that multifocality of the lesion was a significant predictor for upgrading to malignancy, similar to previous studies that showed that multiple papillomas were more likely to be associated with breast cancer than solitary papillomas [24,25].

The mismatch between radiologic findings and pathologic diagnosis is an important issue that requires further evaluation. Some studies have documented that the discordance between radiographic and histologic findings was an important factor that should be evaluated by surgical excision. Thus, inclusion or exclusion of pathologic-radiologic discordant cases may be an important factor leading to variability in upgrade rates. After analyzing 234 benign IDPs, Rizzo et al. [26] reported the rate of upgrading to DCIS and invasive carcinoma as 8.9% and to ADH as 17.9%. Shin et al. [27] showed that an upgrade rate to DCIS and invasive carcinoma was 14% of 86 benign IDPs diagnosed by CNB. Mercado et al. [28] reported that 17% of 36 IDPs were upgraded to ADH. Other studies have reported similar high upgrade rates though these results may raise doubts about the definition of an upgrade [1,29,30].
Collectively, these studies included pathologic-radiologic discordant cases in their analyses or failed to document pathologic-radiologic concordance [1,26-30], leading to falsely high upgrade rates. Shin et al. [27] reported that the upgrade rate to malignancy was higher in imaging-pathologic discordant lesions than in concordant lesions. However, recent studies reported that the upgrade rate for benign IDP is low when the pathologic-radiologic discordant cases are excluded [10,11].

Although physical findings such as a palpable mass and nipple discharge may not predict the risk of upgrading, lesions with such manifestations require careful evaluation and close observation and eventually need excision even if the pathologic diagnosis on CNB was benign. Nakhlis et al. [10] showed that the actual rate of upgrading in their study was 0% when they excluded both of the two patients from their cohort who presented with a clinically suspicious palpable mass. Other studies shared the same perspective, excluding symptomatic patients from their analyses of upgrading of benign IDP [8,19]. We agree that any patient with symptoms such as a palpable mass or nipple discharge should be treated by excision. Thus, of the 383 benign IDP diagnosed by CNB in our study, none of the cases were truly upgraded lesions when we excluded all three cases with clinical symptoms for which surgical treatment is indicated. Of the 17 cases upgraded to high-risk lesions, two cases had pathologic-radiologic discordance, and three cases had clinical symptoms. Therefore, the true upgrade rate to high-risk lesions was 3.1%. Given our results, close clinical and radiologic observation appear to be adequate for patients with benign IDP on CNB under proper clinical settings.

Although IDP has a relatively simple histologic definition, it encompasses a wide variety of lesions. Papillary lesions are often diagnostically challenging for pathologists. IDP may have a complex glandular architecture and epithelial hyperplasia; histologic distinctions between luminal epithelial and myo-epithelial cells or benign hyperplasia and atypical hyperplasia can be subtle, leading to misinterpretations on CNB. Thus, accurate interpretation by an experienced pathologist and an adequate amount of an accurately-targeted specimen are essential for correct diagnosis. In our institution, all breast CNBs were diagnosed by an experienced breast pathologist (S.Y.P.), which can affect diagnostic accuracy. It was reported that one of the reasons for such diagnostic difficulties might be the limited amounts and fragmentation of the samples [16]. Renshaw et al. [3] pointed out that the incidence of upgrading after excision was associated with the adequacy of sampling in biopsy specimens. Several studies have shown different upgrading rates of benign IDP to malignancy depending on the needle gauge used during biopsy [18,19]. In the current study, the number of tissue cores was sufficient with a median value of 5.0, which appears to have contributed to the low rate of upgrades.

In conclusion, the most significant finding of our study is that the rate of upgrading to malignancy of benign IDP without atypia diagnosed by CNB is very low. Moreover, when we excluded cases with suspicious clinical symptoms, the true rate of under-diagnosis in our cohort was 0%. For this reason, caution should be exercised in recommending surgical management for all benign IDPs. Our study suggests that patients with benign IDPs diagnosed by CNB who have solitary lesions without clinically suspicious symptoms and, in particular, no concurrent contralateral breast cancer may be candidates for close observation rather than prompt excision. However, due to the small number of cases upgraded to malignancy in this study, further large-scale studies are warranted to support this suggestion.

**CONFLICT OF INTEREST**

The authors declare that they have no competing interests.

**REFERENCES**

1. Cyr AE, Nowack D, Trinkausk K, Margenthaler JA, Gillanders WE, Eberlein TJ, et al. Are we overtreating papillomas diagnosed on core needle biopsy? Ann Surg Oncol 2011;18:946-51.
2. Gendler LS, Feldman SM, Balassanian R, Riker MA, Frencher SK, Whelan DB, et al. Association of breast cancer with papillary lesions identified at percutaneous image-guided breast biopsy. Ann J Surg 2004;188:365-70.
3. Renshaw AA, Derhagopian RP, Tizol-Blanco DM, Gould EW. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol 2004;122:217-21.
4. Rizzo M, Lund MJ, Oprea G, Schmiedjeran M, Wood WC, Mosunjac M. Surgical follow-up and clinical presentation of 142 breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy. Ann Surg Oncol 2008;15:1040-7.
5. McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ. Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? Ann Surg Oncol 2012;19:3264-9.
6. Shino S, Tsuda H, Yoshida M, Jimbo K, Asaga S, Hojo T, et al. Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features. Pathol Int 2015;65:293-300.
7. Ahmadiyeh N, Stoleru MA, Raza S, Lester SC, Golshan M. Management of intraductal papillomas of the breast: an analysis of 129 cases and their outcome. Ann Surg Oncol 2009;16:2264-9.
8. Bennett LE, Ghate SV, Bentley R, Baker JA. Is surgical excision of core biopsy proven benign papillomas of the breast necessary? Acad Radiol 2010;17:553-7.
9. Ko D, Kang E, Park SY, Kim SM, Jang M, Yun B, et al. The management

https://doi.org/10.4048/jbc.2018.21.1.80
strategy of benign solitary intraductal papilloma on breast core biopsy. Clin Breast Cancer 2017;17:367-72.

10. Nakhlis F, Ahmadyeh N, Lester S, Raza S, Lotfi P, Golshan M. Papilloma on core biopsy: excision vs. observation. Ann Surg Oncol 2015;22:1479-82.

11. Pareja F, Corben AD, Brennan SB, Murray MP, Bowser ZL, Jakate K, et al. Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: rate of upgrade to carcinoma at excision. Cancer 2016;122:2819-27.

12. Carder PJ, Garvican J, Haigh I, Liston JC. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast. Histopathology 2005;46:320-7.

13. Liberman L, Bracero N, Vuolo MA, Dershaw DD, Morris EA, Abramson AF, et al. Percutaneous large-core biopsy of papillary breast lesions. AJR Am J Roentgenol 1999;172:331-7.

14. Liberman L, Drotman M, Morris EA, LaTrenta LR, Abramson AF, Zakowski MF, et al. Imaging-histologic discordance at percutaneous breast biopsy. Cancer 2000;89:2538-46.

15. Mercado CL, Hamele-Bena D, Singer C, Koenigsberg T, Pile-Spellman E, Higgins H, et al. Papillary lesions of the breast: evaluation with stereotactic directional vacuum-assisted biopsy. Radiology 2001:221:650-5.

16. Jakate K, De Brot M, Goldberg F, Muradali D, O'Malley FP, Mulligan AM. Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses. Am J Surg Pathol 2012;36:544-51.

17. Chang JM, Moon WK, Cho N, Han W, Noh DY, Park IA, et al. Risk of carcinoma after subsequent excision of benign papilloma initially diagnosed with an ultrasound (US)-guided 14-gauge core needle biopsy: a prospective observational study. Eur Radiol 2010;20:1093-100.

18. Kil WH, Cho EY, Kim JH, Nam SI, Yang JH. Is surgical excision necessary in benign papillary lesions initially diagnosed at core biopsy? Breast 2008;17:258-62.

19. Holley SO, Appleton CM, Ferria DM, Reichert VC, Warrick J, Allred DC, et al. Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy. Radiology 2012:265:379-84.

20. Youk JH, Kim EK, Kwak JY, Son EJ, Park BW, Kim SI. Benign papilloma without atypia diagnosed at US-guided 14-gauge core-needle biopsy: clinical and US features predictive of upgrade to malignancy. Radiology 2011;258:81-8.

21. Puglisi F, Zuiani C, Bazzocchi M, Valient F, Aprile G, Pertoldi B, et al. Role of mammography, ultrasound and core biopsy in the diagnostic evaluation of papillary breast lesions. Oncology 2003;65:311-5.

22. Hong YY, Song BJ, Jung SS, Kang BJ, Kim SH, Chae BJ. Predictive factors for upgrading patients with benign breast papillary lesions using a core needle biopsy. J Breast Cancer 2016;19:410-6.

23. Schacht DV, Yamaguchi K, Lai J, Kulkarni K, Sennett CA, Abe H. Importance of a personal history of breast cancer as a risk factor for the development of subsequent breast cancer: results from screening breast MRI. AJR Am J Roentgenol 2014;202:289-92.

24. Harjit K, Willsher PC, Bennett M, Jackson LR, Metcalf C, Saunders CM. Multiple papillomas of the breast: is current management adequate? Breast 2006;15:777-81.

25. Lewis JT, Hartmann LC, Vierkant RA, Maloney SD, Shane Pankratz V, Allers TM, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol 2006;30:665-72.

26. Rizzo M, Linebarger J, Lowe MC, Pan L, Gabram SG, Vasquez L, et al. Management of papillary breast lesions diagnosed on core-needle biopsy: clinical pathologic and radiologic analysis of 276 cases with surgical follow-up. J Am Coll Surg 2012;214:280-7.

27. Shin HJ, Kim HH, Kim SM, Yang HR, Sohn JH, Kwon GY, et al. Papillary lesions of the breast diagnosed at percutaneous sonographically guided biopsy: comparison of sonographic features and biopsy methods. AJR Am J Roentgenol 2008;190:630-6.

28. Mercado CL, Hamele-Bena D, Oken SM, Singer CI, Cangiarella J. Papillary lesions of the breast at percutaneous core-needle biopsy. Radiology 2006;238:801-8.

29. Skandarajah AR, Field L, Yuen Larn Mou A, Buchanan M, Evans J, Hart S, et al. Benign papilloma on core biopsy requires surgical excision. Ann Surg Oncol 2008;15:2272-7.

30. Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, et al. Papillary lesions of the breast diagnosed using core needle biopsies. Exp Ther Med 2011;2:1069-72.